FibroGen, Inc (NASDAQ:FGEN) – Analysts at William Blair reduced their FY2019 earnings per share estimates for shares of FibroGen in a research report issued to clients and investors on Wednesday. William Blair analyst A. Hsieh now expects that the biopharmaceutical company will earn $1.41 per share for the year, down from their prior estimate of $5.29. William Blair currently has a “Outperform” rating on the stock.

FibroGen (NASDAQ:FGEN) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.01). FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. The business had revenue of $29.00 million for the quarter, compared to analysts’ expectations of $34.80 million.

WARNING: “FY2019 Earnings Estimate for FibroGen, Inc Issued By William Blair (FGEN)” was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/09/15/fy2019-earnings-estimate-for-fibrogen-inc-issued-by-william-blair-fgen.html.

A number of other equities research analysts have also issued reports on the stock. Stifel Nicolaus restated a “buy” rating and issued a $80.00 target price on shares of FibroGen in a research note on Thursday. Jefferies Group LLC restated a “buy” rating and issued a $75.00 target price on shares of FibroGen in a research note on Tuesday. Leerink Swann restated an “outperform” rating and issued a $82.00 target price (up previously from $52.00) on shares of FibroGen in a research note on Tuesday, August 8th. Citigroup Inc. upped their target price on shares of FibroGen from $48.00 to $65.00 and gave the company a “top pick” rating in a research note on Tuesday, August 8th. Finally, BidaskClub lowered shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $60.17.

FibroGen (NASDAQ:FGEN) traded up 0.29% during mid-day trading on Friday, hitting $52.25. The company had a trading volume of 732,845 shares. The firm’s market capitalization is $3.72 billion. The company has a 50-day moving average price of $42.78 and a 200 day moving average price of $31.87. FibroGen has a 12 month low of $15.60 and a 12 month high of $52.70.

Several large investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in shares of FibroGen by 15.1% during the 2nd quarter. Vanguard Group Inc. now owns 5,808,439 shares of the biopharmaceutical company’s stock valued at $187,612,000 after buying an additional 761,421 shares during the last quarter. BlackRock Inc. grew its position in shares of FibroGen by 12.3% during the 2nd quarter. BlackRock Inc. now owns 5,001,406 shares of the biopharmaceutical company’s stock valued at $161,545,000 after buying an additional 546,587 shares during the last quarter. FMR LLC grew its position in shares of FibroGen by 96.9% during the 2nd quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock valued at $107,753,000 after buying an additional 1,641,423 shares during the last quarter. State Street Corp grew its position in shares of FibroGen by 16.4% during the 2nd quarter. State Street Corp now owns 1,763,387 shares of the biopharmaceutical company’s stock valued at $56,962,000 after buying an additional 248,922 shares during the last quarter. Finally, Hillhouse Capital Management Ltd. grew its position in shares of FibroGen by 75.0% during the 2nd quarter. Hillhouse Capital Management Ltd. now owns 1,750,000 shares of the biopharmaceutical company’s stock valued at $56,525,000 after buying an additional 750,000 shares during the last quarter. 47.49% of the stock is owned by institutional investors and hedge funds.

In related news, Director Kalevi Kurkijarvi sold 2,000 shares of the business’s stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $33.45, for a total transaction of $66,900.00. Following the completion of the sale, the director now owns 32,000 shares of the company’s stock, valued at approximately $1,070,400. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Pat Cotroneo sold 95,000 shares of the business’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $50.61, for a total transaction of $4,807,950.00. Following the sale, the vice president now directly owns 173,366 shares of the company’s stock, valued at approximately $8,774,053.26. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 423,941 shares of company stock valued at $17,310,813. Insiders own 14.90% of the company’s stock.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Earnings History and Estimates for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.